If you've already registered, please click here to log in to the webcast
The past 10 years have seen a rapid evolution of therapeutic T-Cell redirection immunotherapies culminating in the approval of two important new treatment modalities: Chimeric Antigen Receptor T-cells (CAR-T) and Bispecific T-cell Engagers (BiTE®s). Alternative scaffolds and antibody formats are being explored to further optimise tumour targeting of T-cell redirection therapies. Newer and more diverse formats for bispecific antibody T-cell engagers and CAR-T cells are being developed to enhance the therapeutic window, tune target affinity binding and enhance biomarker specificity to minimise off-target toxicity. The extension of bispecific antibody T-cell engagers and CAR-T to the treatment of solid tumours is a holy grail for immunotherapy as solid tumours present a significantly larger unmet medical need than haematological malignancies.
In this webcast, speakers will introduce the unique benefits of the VHH antibodies generated from the hLlamdA™ synthetic library and summarize how single domain VHH antibodies can be engineered to tune their binding selectivity and specificity for antigen targeting and be applied to optimize the next generation of these important new therapeutic modalities.